Recursion Pharmaceuticals cleared an FDA IND for REC-7735, its AI-designed PI3Kα H1047R inhibitor, according to the company’s quarterly update. The IND clearance enables a phase I/II study for patients with select PIK3CA H1047R-mutant solid tumors, with initiation planned for the second half of this year. PI3Kα H1047R is a well-defined oncogenic mutation that can drive tumor growth through PI3K/AKT signaling, making it a precision oncology target. Recursion’s approach combines computational target discovery with downstream clinical development through an early pipeline built to translate AI validation into clinical biology. The start of the trial marks a concrete milestone for the program beyond preclinical characterization, moving the asset into patient dosing and safety/early efficacy assessment.